Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Revolution Medicines, Inc.
Incyte Corporation
Pfizer
National Institutes of Health Clinical Center (CC)
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Memorial Sloan Kettering Cancer Center
INSYS Therapeutics Inc